Tumor-on-a-chip with micropillar segmentation for immunotherapy screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current clinical tools and biomarkers are inadequate for accurately characterizing tumor microenvironments and predicting immunotherapy efficacy in neuro-oncology, due to limitations in conventional measurement methods and the intrinsic heterogeneity and complexity of tumor immunity, necessitating a patient-specific biomimetic model for personalized treatment guidance.
Innovation Solution
A tumor-on-a-chip device is developed, featuring a cartridge with a central chamber partitioned by micropillars to mimic a tumor microenvironment, incorporating endothelial cells and tumor cells, and equipped with sensors for monitoring treatment responses, allowing for the replication of various cancer types and evaluation of anti-cancer therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional measurement methods are used to characterize tumor microenvironments, then the measurement process is simple, but the accuracy and reliability of predicting immunotherapy efficacy deteriorates due to inability to capture heterogeneity and mechanistic details
Solution Approach 1:
The tumor microenvironment is segmented into distinct spatial zones (outer region with endothelial cells, middle region with tumor cells, inner region for media perfusion) using micropillar partitions. This segmentation allows independent characterization of different TME components and their interactions, enabling accurate prediction of immunotherapy efficacy while maintaining manageable system complexity through modular design.
Solution Approach 2:
A micropillar array serves as an intermediary structure that physically partitions the chip while allowing fluid and molecular exchange between regions. The micropillars enable spatial organization of different cell types and facilitate the study of tumor-immune interactions without requiring complex multi-chamber systems, thus improving measurement precision while controlling device complexity.
2Reliability
If patient-specific biomimetic models are developed to capture tumor heterogeneity and immune interactions, then the predictive accuracy of immunotherapy response improves, but the device complexity and manufacturing difficulty increase
Solution Approach 1:
The micropillar array structure serves multiple functions: it partitions spatial zones, enables fluid flow control, supports cell culture, and facilitates sensor integration. This multi-functionality allows a single structural element to address multiple requirements for patient-specific modeling, improving reliability while simplifying manufacturing compared to assembling multiple separate components.
Solution Approach 2:
The device allows easy adjustment of cell types, ratios, and microenvironmental parameters (oxygen concentration, pH, nutrient supply) by changing culture conditions rather than redesigning the device structure. This parameter-based customization enables patient-specific modeling while maintaining ease of manufacture through software-controlled variable adjustment.
3Productivity
If high-throughput screening platforms are implemented to test multiple therapies, then the productivity of preclinical testing increases, but the device complexity and cost increase
Solution Approach 1:
Multiple therapy testing capabilities are merged into a single chip platform by integrating different drug delivery channels and sensor arrays. The micropillar structure enables simultaneous testing of multiple therapeutic interventions in parallel within one device, increasing productivity while avoiding the complexity of using multiple separate devices.
Solution Approach 2:
The device incorporates integrated sensors that automatically monitor and report on treatment responses without requiring external intervention. The system self-regulates media perfusion and waste removal through the micropillar architecture, reducing operational complexity while enabling high-throughput screening through automated data collection from multiple parameters simultaneously.
Data Source
AI summary
The present invention provides devices that replicate tumor microenvironments in a microfluidic chip. The devices can be used to model certain disease states related to tumor microenvironments. The devices can be adapted to replicate tumor microenvironments from patient-specific cells such that treatment conditions can be modeled and tailored to individual patients. In some embodiments, the devices are suitable for evaluating cancer therapies on a patient-specific basis.